Hikma Pharmaceuticals (LON:HIK) Stock Price Crosses Above 200-Day Moving Average of $1,918.45

Hikma Pharmaceuticals PLC (LON:HIK) shares passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of GBX 1,918.45 ($25.09) and traded as high as GBX 1,928.18 ($25.21). Hikma Pharmaceuticals shares last traded at GBX 1,917 ($25.07), with a volume of 319,355 shares trading hands.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on HIK shares. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a GBX 2,750 ($35.96) target price on shares of Hikma Pharmaceuticals in a research report on Tuesday, June 18th. Berenberg Bank raised Hikma Pharmaceuticals to a “buy” rating and upped their target price for the stock from GBX 2,100 ($27.46) to GBX 2,400 ($31.38) in a research report on Monday, September 2nd. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of GBX 2,325 ($30.40).

Hikma Pharmaceuticals Price Performance

The company has a debt-to-equity ratio of 55.48, a quick ratio of 1.27 and a current ratio of 1.66. The business has a 50 day simple moving average of GBX 1,926.45 and a 200-day simple moving average of GBX 1,918.45. The firm has a market cap of £4.22 billion, a price-to-earnings ratio of 2,949.23, a P/E/G ratio of 2.38 and a beta of 0.41.

Hikma Pharmaceuticals Cuts Dividend

The business also recently announced a dividend, which will be paid on Friday, September 20th. Investors of record on Thursday, August 15th will be given a dividend of $0.32 per share. The ex-dividend date of this dividend is Thursday, August 15th. This represents a dividend yield of 1.37%. Hikma Pharmaceuticals’s payout ratio is 9,538.46%.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.